Wed, Jan 28, 2015, 7:29 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Oncolytics Biotech Inc. Message Board

  • hgff101 hgff101 Feb 12, 2013 3:44 PM Flag

    Immunity compromise and recent Harrington work

    Harrington, one of the principle researchers in the SCCHN trials, published some work about a year ago showing how Reo attaches to blood cells in a manner that allows it to hide from the immune system.

    Shortly after the article was published, the several NCIC trials were announced.

    Its not about immunity, its about getting enough Reo in the system. The dosing of Reo in these trials is far more than what one would experience in the normal course of natural Reo infection.

    The current thinking on use of chemo is based on the supposition that chemo makes the tumors more porous and permeable to Reo infiltration.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Right on. And I believe squamous cell is the most porous of them all, which is why reovirus can enter more easily compared to adenocarcinomas.

      The market for squamous cell cancers is quite large.

      And of course the market for metastatic cancer is the biggest of them all.

      It's high time to get Reo to market. And I think the FDA sees that. Otherwise would they have let ONCY alter the phase III for metastatic like that?

      Sentiment: Strong Buy

0.4606-0.0094(-2.00%)Jan 28 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Facebook, Inc.
NASDAQWed, Jan 28, 2015 4:00 PM EST
QUALCOMM Incorporated
NASDAQWed, Jan 28, 2015 4:00 PM EST
Core Laboratories NV
NYSEWed, Jan 28, 2015 4:01 PM EST